A Multi-Centre, Randomized, Double-Blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492.

Trial Profile

A Multi-Centre, Randomized, Double-Blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Selurampanel (Primary) ; Sumatriptan
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Aug 2013 Results published in the Cephalalgia.
    • 31 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top